Krystal Biotech, Inc.
KRYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5,111 | $3,974 | $5,195 | $4,505 |
| - Cash | $393 | $354 | $309 | $345 |
| + Debt | $2 | $2 | $10 | $7 |
| Enterprise Value | $4,720 | $3,622 | $4,896 | $4,167 |
| Revenue | $98 | $96 | $88 | $91 |
| % Growth | 1.8% | 8.9% | -3.2% | – |
| Gross Profit | $92 | $89 | $83 | $86 |
| % Margin | 94.2% | 92.5% | 94.3% | 94.6% |
| EBITDA | $50 | $41 | $38 | $43 |
| % Margin | 50.7% | 42.5% | 42.9% | 47.1% |
| Net Income | $79 | $38 | $36 | $45 |
| % Margin | 81.2% | 39.9% | 40.5% | 49.9% |
| EPS Diluted | 2.66 | 1.29 | 1.2 | 1.52 |
| % Growth | 106.2% | 7.5% | -21.1% | – |
| Operating Cash Flow | $40 | $53 | $31 | $53 |
| Capital Expenditures | -$2 | -$2 | -$6 | -$1 |
| Free Cash Flow | $38 | $51 | $25 | $52 |